Overview: OncoPro OCA Plus Tumor Profiling TestIntroduction: The OncoPro OCA Plus Tumor Profiling Test profiles tumors for comprehensive cancer diagnosis, aiding personalized treatment. Following 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected cancers, such as lung or breast cancer.
Other Names: OCA Plus Assay, Comprehensive Tumor Profile Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Tumor profiling began in the 2010s with NGS advancements. Comprehensive panels improved personalized treatment in the 2010s.
Purpose: Profiles tumors for comprehensive cancer diagnosis, guides personalized treatment, and evaluates patients with cancer symptoms.
Test Parameters: 1. Tumor Profile Genes
Pretest Condition: No fasting required. Collect whole blood or tissue. Report history of pain, weight loss, or cancer symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Tissue (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document pain, weight loss, lumps, or family history of cancer. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, cancer profiling implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to profile tumor genes (e.g., EGFR, KRAS). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for cancer diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations guide personalized therapies, such as EGFR inhibitors. Negative results may require additional profiling.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Tissue biopsy, imaging (CT/MRI), or tumor markers to confirm cancer diagnosis.
Test Limitations: Not all cancers have actionable mutations; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Tumor Profiling Guidelines, 2023; Journal of Clinical Oncology, Mosele F, 2022.
